8-K: Day One Biopharmaceuticals Reports Strong Q4 and Full Year 2024 Financial Results Driven by OJEMDA Sales

Day One Biopharmaceuticals announces positive financial results for Q4 and full year 2024, driven by OJEMDA sales and corporate progress.

Summary

• Day One Biopharmaceuticals reported its fourth quarter and full year 2024 financial results.
• OJEMDA net product revenues reached $29.0 million for the fourth quarter and $57.2 million for the full year ended December 31, 2024.
• License revenue from the sale of ex-U.S. commercial rights for tovorafenib were $0.2 million and $73.9 million for the fourth quarter and full year ended December 31, 2024, respectively.
• Research and development expenses were $61.8 million for the fourth quarter and $227.7 million for the full year, compared to $37.3 million and $130.5 million for the same periods in 2023.
• Selling, general, and administrative expenses were $29.8 million for the fourth quarter and $115.5 million for the full year, compared to $22.2 million and $75.6 million for the same periods in 2023.
• Net loss totaled $65.7 million for the fourth quarter and $95.5 million for the full year ended December 31, 2024.
• The company ended 2024 with $531.7 million in cash, cash equivalents, and short-term investments.
• Full enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial is expected in the first half of 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a solid cash position, and pipeline advancements. While there are net losses, the overall tone is optimistic due to the successful launch of OJEMDA and future growth prospects.

Positives

• OJEMDA's strong launch and revenue growth indicate successful commercialization.
• The company has a strong cash position of $531.7 million, providing financial flexibility.
• Progress in the DAY301 clinical trial and advancement of FIREFLY-2 trial demonstrate pipeline development.
• OJEMDA received the Exclusively Pediatric designation, reducing Medicaid and 340B minimum rebate percentage from 23.1% to 17.1%.

Negatives

• The company reported a net loss of $65.7 million for Q4 2024 and $95.5 million for the full year.
• Research and development expenses increased significantly due to the DAY301 upfront license payment and dose escalation study milestone.
• Selling, general, and administrative expenses increased due to employee compensation costs and professional service expenses to support the launch of OJEMDA.

Risks

• The company's future performance depends on the continued success of OJEMDA and its pipeline development.
• Clinical trials are subject to inherent risks and uncertainties, which could impact timelines and outcomes.
• The company's financial performance could be affected by global business or macroeconomic conditions.
• The company's reliance on accelerated approval for OJEMDA means continued approval is contingent upon verification of clinical benefit in a confirmatory trial.

Future Outlook

Day One aims to continue driving OJEMDA revenue growth, execute on clinical development for FIREFLY-2 and DAY301, expand its portfolio, and maintain a strong capital position.

Management Comments

• Jeremy Bender, Ph.D., chief executive officer of Day One, stated that the approval of OJEMDA was the catalyst for the company's next stage of growth.
• Jeremy Bender is proud that the team was able to offer OJEMDA to so many relapsed or refractory pediatric low-grade glioma (pLGG) patients in the first months of launch.
• Management believes they are on a path to long-term, durable growth and to the realization of Day One's mission with OJEMDA as their foundation and a strong balance sheet.

Industry Context

Day One is focused on addressing the unmet need for targeted therapies in pediatric cancer, a field that has historically been underserved. The company's progress with OJEMDA and its pipeline programs positions it as a key player in the development of treatments for pediatric cancers.

Comparison to Industry Standards

• Day One's OJEMDA competes with other therapies targeting BRAF alterations in pLGG, such as MEK inhibitors like selumetinib (Koselugo) from AstraZeneca.
• The $57.2 million in OJEMDA sales in 2024 is a strong start compared to other recent oncology drug launches, but it's still early in the product lifecycle.
• The company's R&D spending is in line with other biopharmaceutical companies focused on clinical-stage development.
• Day One's cash position is robust compared to other companies of similar size and stage, providing a competitive advantage.

Stakeholder Impact

• Shareholders can expect continued focus on revenue growth and pipeline development.
• Employees will be involved in supporting the commercialization of OJEMDA and the advancement of clinical trials.
• Patients will benefit from the availability of OJEMDA and the potential development of new therapies.
• The company's financial stability ensures its ability to meet its obligations to suppliers and creditors.

Next Steps

• Management will participate in the 44th Annual TD Cowen Health Care Conference on March 4, 2025.
• The company will continue to advance enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial.
• Day One will continue to develop DAY301 through Phase 1a/b clinical trials.
• The company will focus on driving OJEMDA revenue growth and establishing it as a standard of care.

Key Dates